Proceedings of ICMMGH 2026 Symposium: Biomedical Imaging and AI Applications in Neurorehabilitation
DOI: 10.54254/2753-8818/2026.AU29482

mRNA Vaccine Breakthroughs in Immune Response and Disease Treatment

Houze Li

Pegasus California School, Qingdao, China
hl6222@nyu.edu

Abstract. Scientific advancements in vaccine technology have found a home in the mRNA vaccine. The remarkable effectiveness of the COVID-19 vaccination program underscores its crucial role in addressing the worldwide public health emergency. In order to examine the scientific process of mRNA vaccine technology and its wider public health implications, this research uses SARS-CoV-2 as a case study. The findings demonstrate that a large-scale therapeutic impact on severe COVID-19 may be achieved using the programmability of sequences carried by mRNA, nucleoside alteration, and lipid nanoparticles (LNP), while simultaneously compressing the design deployment period. The RNA payload and its LNP carrier generate robust adaptive immunity, which includes persistent T cell recognition with potent neutralizing antibodies and conserved epitopes, and a congenital stimulating effect through the production of calibration-assisted responses, the promotion of dendridocyte activation, and the formation of reproductive centers. Although mRNA vaccines have distinct benefits, such as antigen complexity and update flexibility, there are also persistent challenges, such as decreased immunity due to antigen drift, stability limitations caused by cold chain requirements, and cost and accessibility inequalities on a global scale. This paper proposes policy measures and advances in delivery science to ensure fair translation of this multifunctional technology. Future efforts should focus on improving durability, expanding mucosal immunity, combining genomic monitoring with rapid design pipelines, and consolidating mRNA vaccines as a resilient platform for infectious diseases and oncology.

Keywords: mRNA vaccines, lipid nanoparticles, immune mechanisms, global vaccine equity.

1. Introduction

As a programmable immune method, mRNA vaccines guide host cells to express target antigens through in vitro transcription, and lipid nanoparticle (LNP) encapsulation ensures their biological stability and delivery efficiency. Three engineering breakthroughs (nucleoside modification, optimization of untranslated regions, and design of ionizable lipids) have promoted the implementation of this technology, and the COVID-19 epidemic has further verified its advantages - from sequence to clinical cycle, it has shrunk to several months, and the production is updated easily, becoming an information-driven epidemic prevention tool [1].

© 2025 The Authors. This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (https://creativecommons.org/licenses/by/4.0/).

DOI: 10.54254/2753-8818/2026.AU29482

The current research covers the fields of infectious diseases and tumors. Influenza vaccines expand their protection spectrum through multivalent constructs, while vaccines such as RSV and CMV overcome the production difficulties of recombinant proteins. In the field of tumors, personalized neoantigen vaccines are developed based on patient data, and combination therapies and alternative delivery pathways are explored. However, there are limitations in the research, such as the lack of unified protection-related indicators, insufficient quantification of the association between LNP and vaccine persistence, and more validation is needed for the relationship between new antigens in the field of cancer and clinical benefits, and application limitations, such as thermal stability and cost, have not been included in the comprehensive evaluation. There is a lack of integrated analysis that considers mRNA as a platform [2].

In order to solve the above fragmentation problem, this paper constructs a comprehensive framework: based on the COVID-19 vaccine, we associate molecular design and immune response, compare mRNA with other vaccines from multiple dimensions, and finally form a decision matrix matching disease types and mRNA design strategies. Combining multiple types of evidence and incorporating implementation variables, the paper identifies the advantages and improvement directions of mRNA vaccines.

2. mRNA vaccine case validation mechanistic analysis and comprehensive evaluation

2.1. Application and expansion of mRNA vaccines

Under the pressure of the rapidly spreading respiratory pandemic, mRNA vaccination has shifted from a niche experimental method to a pillar of public health. The main benefit is the capacity to program it. The conservative manufacturing chassis, which includes cap chemistry, untranslated region, and ionizable lipid formula, may have its coding sequences changed. Without tearing up the production floor, the design team may go on to the next variation sequence. The time it takes to get from genomic monitoring to practical goods is reduced by this choice of architecture. In addition to speeding up cross-update regulatory learning, it unifies analytical tools for release testing, drug alert, and comparability evaluation [3].

The technology is subjected to diverse demographics, supply constraints, and risk-aware swings when it is launched statewide. Next, real-world efficacy investigations follow the arcs of weakening, promotion, and mutation escape; clinical trials prove protection against symptomatic disorders and significantly lower the probability of disastrous outcomes. Immunological analysis confirms these tendencies. Following the startup, the neutralization titre increased, then fell in accordance with predicted dynamics, and then increased again in response to the booster. Through recurrent antigen exposure, memory B cells diversify their specificity and affinity, allowing them to generate a larger spectrum of antibodies, even under cyclic titer. In response to mutation waves, T cells monitor conserved epitopes and generate anti-hospitalization buffers. The upgrade is worth it since these features rejoin the well-trained memory compartment with each refresh [4].

Distinct dynamics apply to manufacturing. Not cell culture constraints, but RNA synthesis and microfluidic LNP hybridization. Instead of upstream production, filling completion capacity and cold chain integrity are the most intractable constraints. As compared to countries that have long-standing sterile operations, regions without access to glass bottles, stoppers, or deep freezers are falling behind. Regional capabilities are being planted via the technology transfer strategy, but the training of RNA specificity analysis and ionizable lipid processing is still a step that limits the pace of progress. Although the sequence-based platform does ease the technical strain of antigen renewal, it is not a panacea for the last-mile logistical issue, according to experience [5].

DOI: 10.54254/2753-8818/2026.AU29482

Changes in evidence-based public health policy are inevitable. In order to maintain immunogenicity while inhibiting reactivity, the pediatric program modifies the dosage and buffer. By coupling protein or vector enhancement with mRNA induction, the diverse schedule investigates supplementary immune traits. High-risk groups received targeted intervals, and information was provided by observation data on durability and breakthrough patterns. All of these occur under a positive safety net: common, transient systemic symptoms reflect congenital stimulation; rare adverse events, such as myocarditis, are concentrated in specific demographics and included in guidance and risk communication. As a whole, the case study verified the core proposition of the mRNA vaccine: rapid re-template on a stable chassis, strong recall response, and manageable safety features when deployed on a population scale.

The SARS-CoV-2 response is a calibration benchmark because it connects three threads in a single emergency - speed, effectiveness and operational feasibility. Pre-fusion of stable peak structure, capping and polyadenylated transcripts, and LNP cross-program convergence with tuning pKa values. Due to the high incidence, the efficacy readings arrive quickly; the effectiveness data comes from the relevant health records and monitoring systems. The variant-specific booster tested the agile update ability of the platform, while the drug alert system analyzed common reactionary and rare signals that need to change the label or interval adjustment. The lessons of this benchmark summarize: genome monitoring can provide information for the design of the update cycle; the immune memory induced by mRNA is easy to re-engage. The supply chain requires as much engineering as the nucleotide chemistry itself [6,7].

2.2. Analysis of core immune mechanisms of mRNA vaccines

The RNA payload and its lipid carrier must begin their duet in the mechanical account. The expression kinetics and antigen encoding are controlled by transcripts, whereas the biological distribution and auxiliary features are shaped by nanoparticles. The immune system reads two layers, sometimes cooperative and sometimes cross-cutting. Adjusting this interaction - inhibiting excessive translation to block interferon while retaining dendroidal cell permission-explains most of the performance of the platform.

2.2.1. The innate immune stimulation auxiliary of the mRNA lipid nanoparticle complex

Cytoplasmic receptors such as endochromosomes TLR7/8 and RIG-I and MDA5 detect single-stranded sequences and dsRNA pollutants, triggering the cascading, NF-κB activation and chemokine release of type I/III interferon. Uncontrolled signals can limit translation by inducing PKR and OAS/RNase L pathways, causing cells to starve the protein from being produced by the vaccine. The chemically modified nucleotide and strict purification steps lowered the upper limit, creating a window for translation, and the measured interferon pulse-driven antigen to present cell maturity [8].

LNP adds a unique layer. Protonated ionizing lipids in the endosome help the endosome to escape and can participate in the inflammatory body-linking pathway; help phospholipids and cholesterol stabilize the double layer and affect the fusion tendency; polyethylene glycol lipidization regulates the cycle time, but also interfaces with complements and pre-existing anti-polyethylene glycol antibodies. Composite signatures tend to be tilted by Th1. Up-regulated IL-12 and interferon-stimulated genes are conducive to the cross-presentation of conventional type 1 dendritic cells, which is a prerequisite for CD8+ induction. The size, time and tissue positioning of this innate

DOI: 10.54254/2753-8818/2026.AU29482

procedure determine whether antigens and co-stimuli coincide in the same dendritic cells, which is the sweet spot of immunology [9].

Dynamics is very important. In most formulas, the antigen expression increases within a few hours and decreases within a few days. Congenital cytokines are crowned in a similar window. Dose selection, lipid chemistry and drug route will change these curves. Higher doses can produce more antigens and more interferons. If the translation becomes self-limiting, the return will be reduced. Less inflammatory lipids can prolong the expression, but they may reduce the activation of dendritic cells unless it is compensated for by scheduling or pairing with exogenous adjuvants. Intramuscular injection involves the drainage of lymph nodes; intradermal or intranodular delivery concentrates the payload in a professional APC bed; the mucosal pathway longs for the tissue residence procedure of the respiratory interface, but must overcome the mucus barrier, enzyme degradation and ciliary removal. Therefore, the auxiliary role of LNP is not a single switch, but an adjustable spectrum that interacts with the innate footprint of the transcript itself [10].

2.2.2. Adaptive immune induction of body fluid B cell antibody and T cell response

mRNA-encoded antigens enter the lymphatic region in the form of a strong reproductive center and efficient MHC I presentation. In terms of body fluids, the persistent reproductive center in the drainage node allows the cycle of mutation and selection, thus improving antibody affinity and diversifying the surface coverage. The resulting antibodies are biased towards IgG subclasses with strong Fc-mediated effector functions - ADCC, ADCP and complement deposition - extending the protection beyond neutralization. The memory B cell pool expands with repeated exposure through booster shots or infection, and a subset differentiates into bone marrow resident plasma cells that maintain the basal titre. Coordination depends on the help of T follicles to help cells; the innate environment created by mRNA/LNP is conducive to the development of Tfh through cytokines such as IL-6 and type I interferon, so that the system aligns high-quality antibodies to mature [11].

The cell arm benefits from the endogenous synthesis of antigens. The transfected cells present peptides through MHC I type, and cDC1 cross-presents enhanced CD8+ detonation. The CD4+ reaction showed Th1 bias, and the production of IFN-γ and IL-2 was associated with antiviral efficacy and reduced the risk of Th2 distortion pathology. The epitope width in T cell response usually exceeds the protein subunit, because intracellular processing has a wider peptide space than exogenous ingestion. This breadth becomes crucial under antigen drift: antibody binding sites may change, but many T cell targets remain conserved. The new antigen undergoes the same redeployment in a cancer setting. In this case, the obstacles are distinct: the immune system's selective exclusion of "cold" tumors, the exhaustion caused by prolonged exposure to antigens, and the immune system's editing of tumors. One approach to preserving T cell function and increasing intratumor infiltration is to combine it with cytokine engineering, co-stimulating agonists, or checkpoint inhibitors. Antigen loading and dose intervals influence T cell adaptability in the same way as they influence antibody maturation; longer intervals may enhance memory quality, while shorter intervals might worsen expansion and put functional fatigue at risk [12].

DOI: 10.54254/2753-8818/2026.AU29482

2.3. Synthesis, comparison, challenges and outlook of mRNA vaccines

2.3.1. Platform comparison: mRNA vaccines versus traditional vaccine platforms for diverse diseases

The limitations of real-world deployment and the biological requirements of tumors or infections should be considered while choosing a platform. The advantages of mRNA are not universal; they are conditional on the condition. Understanding these conditions requires a cross-sectional study of the alternative platform and a frank assessment of logistical and economic factors. Speed and the updated agility are the most obvious advantages. Once the coding sequence is ready, in vitro transcription and lipid formulation will be carried out without the need for the typical time-consuming cell culture or protein purification of subunit vaccines. The viral vector also provides a rapid prototype, but repeated drug delivery will encounter anti-carrier immunity, which will slow the reaction. Inactivated or live attenuated vaccines provide long-term durability for some pathogens, but attenuated strains need to be carefully balanced between safety and immunogenicity, and are not suitable for overnight replacement. Protein subunits paired with strong adjuvants can reach high and titers, and usually enjoy good stability, although they face antigen design challenges when targets are large, polymers or membranes embedded.

Broadness and organizational positioning transfer calculus according to the disease category. For rapidly drifting respiratory viruses, the retemplate speed is decisive; the booster becomes part of the control strategy, not the failure of the primary series. For complex herpes viruses, such as CMV or EBV, mRNA can encode large glycoprotein complexes that are difficult to express as recombinant proteins with the correct quaternary structure, tilting the field towards RNA. For intracellular bacteria and parasites, the bottleneck is not the coding itself, but the detection of antigens and the need for strong Th1/Th17 characteristics; here, unless the mRNA formula contains congenital agonists and the delivery route is biased towards the right tissue compartment, the adjuvant or live vector may compete. In oncology, personalized vaccines take advantage of the short design of mRNA to the dose interval and the convenience of coding dozens of new antigens; fixed platforms cannot match the personalized speed, although in some cases they may provide longer-lived antigen libraries.

The reactivity and safety characteristics are different in terms of characteristics. mRNA tends to cause transient systemic symptoms consistent with interferon biology, and in rare cases, it can be associated with inflammatory signals in specific demographics. Adenovirus vectors must solve pre-existing anti-vector immunity and very rare thrombosis events. Protein subunits transfer the burden of immune stimulation to external adjuvants, which present their own local and systemic effect patterns. Manufacturing risks also vary: RNA needs to control dsRNA by-products and capping efficiency; proteins must manage glycosylation heterogeneity; viral vectors increase the complexity of infectious titers and replicable pollutants. Regulatory comparability can be said to be the most mature for mRNA, because the chassis concept allows institutions to evaluate sequence updates based on fixed panels of key quality attributes.

2.3.2. Key challenges: durability, stability, cost and global access to mRNA vaccines

Durability is still the most controversial scientific issue. Early protection against infection is reduced with the reduction of antigen drift and time; the defense against serious diseases is more lasting, supported by T cell response and affinity-mature memory B cells. The original antigen imprint shape recall sometimes turns the reaction to familiar epitopes at the expense of new variant patterns. It is

DOI: 10.54254/2753-8818/2026.AU29482

difficult to obtain mucosal immunity through intramuscular injection; tissue resident memory in the upper respiratory tract or intestine requires different transport physics, formula and safety considerations.

Stability is a practical constraint with practical consequences. At present, many LNP formulas have limited thermal stability windows. They must be refrigerated or frozen and used quickly after thawing. There are freeze-drying or dry powder formats in the development pipeline, but the wide deployment depends on consistent reorganization performance, proven long-term stability, and compatibility with automatic filling. The cost is determined by special inputs - cap analogues, high-purity nucleotides, ionizing lipids, polyethylene glycolated components - and the process analysis of RNA integrity, particle size, encapsulation efficiency and residual solvents. With the expansion of demand, lipid synthesis capacity and chromatographic resin have become the pressure points of the supply chain.

Visit is the place where biology and policy meet. Manufacturing is geographically concentrated; many regions lack microfluid mixers, high-grade ethanol treatment, and QC instruments for RNA and nanoparticles. The intellectual property landscape surrounding ionizable lipids, PEG variants and capping chemicals complicates local production. The regulatory channels for updating strains or variants in various jurisdictions are still in coordination, which increases the friction of global coordination. The deployment also depends on the public's confidence. Rare adverse events, even if they obviously exceed the benefits, may inhibit absorption without careful communication, especially in an information environment that is easily distorted.

2.3.3. Strategic recommendations: future research directions and policy measures for mRNA technology

Progress will come from synchronous progress in molecular design, delivery science, analysis, manufacturing and governance. In terms of molecular structure, the dose retention strategy deserves a head-to-head test with a coordinated endpoint. Self-amplification RNA can reduce the dose and expand the expression at the same time; circular RNA promises resistance to exonuclease and unique translation kinetics; refined UTR and codon use libraries can shape the expression kinetics without expanding the innate footprint. Antigen engineering should go beyond strain matching and turn to structure-guided conservative epitope exposure, reproductive system targeting schemes for recruiting rare B cell precursors, and immune focusing design against imprints. In cancer, the pipeline should integrate immunopeptidomics and clonal awareness rankings to prioritize new antigens that are most likely to appear and be immunogenic in the body.

At the time of delivery, the next generation of ionized lipids with cleaner biodegradation and lower complement activation is a priority, as well as an alternative to PEG to reduce allergies and anti-PEG immunity. Through tissue targeting of ligands (mannose for dendritic cells, integrin-binding peptides for mucosal return, and turnstones in certain bone marrow compartments), low-dose efficiency can be improved. Optimal thermal stability, droplet size distribution, shear stability, and mucus contact are all aspects of sedimentation physics that should be considered throughout the mucosal formula's construction. To guarantee uniform dosage across devices and situations, thorough human-factors studies are necessary for aerosol administration.

When it comes to analytics and correlates, the sector may use standardized assay panels that include composite correlates such as neutralization breadth, Fc-effector profiles, B-cell repertoire metrics, and T-cell polyfunction. When conducting placebo-controlled studies becomes impractical, hierarchical models may incorporate data from many trials and platforms, allowing for immunobridging. To eliminate confusion for regulators and manufacturers, bioinformatics pipelines

DOI: 10.54254/2753-8818/2026.AU29482

that link genomic monitoring with antigen selection should disclose pre-specified guidelines for when updates are triggered, which antigen sets qualify, and which tests show non-inferiority or superiority.

To lessen manufacturing-related supply-chain risks, establish regional centers that can synthesize RNA, formulate LNPs, and complete sterile filling. In addition to formulae, technology transfer should include process analysis, equipment calibration, environmental monitoring, and microfluid mixer troubleshooting. The workforce's growth in areas such as RNA-savvy analytical chemists, lipid processing engineers, and dsRNA determination regulators will dictate the real pace of large-scale. Procurement incentives should be tied to investments in freeze-drying platforms and disposable systems to decouple manufacturing from freezers. These utilities could encourage thermally robust demonstrations and lower dosage formats.

A policy coordination mechanism is required to bring public health objectives into line with incentives. To provide room for regional producers and keep profits for inventors via tiered royalties, patent pools or voluntary licensing centered on important lipid families and that chemistry might be considered. Field restrictions will drive innovation as the industry prioritizes thermal stability, dosage reductions, and a broader spectrum of antigens. Regulatory convergence based on chassis update - fixed panel anchoring, accelerated review of key quality attributes - will lock in speed advantages without eroding safety standards. Global financing facilities can undertake the initial capital of low- and middle-income hubs, provided that they are committed to data transparency and quality benchmarking. Communication strategies should foreground absolute and relative risk, convey uncertainties with candor, and partner with community organizations to maintain trust across booster cycles.

Strategic deployment should match the platform to the biological problem. For drift-prone respiratory viruses, frequent, small antigen updates make sense, possibly with seasonally toggled bivalent or mosaic constructs. For persistent herpesviruses, multi-antigen cocktails that encode complex glycoprotein assemblies and include T-cell targets are more promising. For intracellular bacteria or parasites, pairing mRNA with potent innate agonists and exploring intradermal or intranodal routes may be necessary to reach protective Th1/Th17 profiles. In oncology, individualized vaccines will benefit from shorter design-to-dose intervals, deeper sequencing to capture subclonal neoantigens, and adaptive regimens that respond to clonal evolution during therapy.

3. Conclusion

This paper systematically analyzes mRNA vaccines' value, mechanisms, challenges and prospects via the CAS framework to clarify their role in immunization and oncology. The case study confirms mRNA vaccines became public health pillars during the COVID-19 epidemic, with programmability shortening design-to-clinic timelines; mechanistic analysis shows nucleoside modification and LNP adjuvant effects drive robust innate and adaptive immunity; synthesis highlights their advantages in speed/antigen complexity versus traditional platforms, while identifying durability, cold-chain and access issues. This study integrates fragmented research to provide a holistic view of mRNA vaccines, guiding targeted development for different diseases. Current limitations include modest infection protection durability, weak mucosal immunity and uneven global access; future efforts should focus on self-amplifying/circular RNA, thermostable formulations, regional manufacturing hubs and mucosal delivery to enhance efficacy and equity.

DOI: 10.54254/2753-8818/2026.AU29482

References

[1] Toufik Abdul Rahman, Ogungbemi Evelyn Faith, Oyinbolaji Akinwande Ajetunmobi, Hala Ibrahim Thaalibi, Chinelo Geraldine Ikele, Gargi Gautam... & Godfred Yawson Scott.(2025).Potential of MRNA vaccines for mpox prevention: current evidence and future directions..Annals of medicine and surgery (2012), 87(9), 5650-5660. https: //doi.org/10.1097/MS9.0000000000003558.

[2] Zhen Zhang, Jingli Du, Danyang Zhang, Rui Han, Xueqiong Wu & Yan Liang.(2025). Research progress of mRNA vaccines for infectious diseases.European Journal of Medical Research, 30(1), 792-792. https: //doi.org/10.1186/S40001-025-03060-X.

[3] János Szebeni & Akos Koller.(2025).Multisystem Endothelial Inflammation: A Key Driver of Adverse Events Following mRNA-Containing COVID-19 Vaccines.Vaccines, 13(8), 855-855. https: //doi.org/10.3390/VACCINES13080855.

[4] Miran Jo, Eunjo Lee, Ho Jung Oh, Jin Tae Hong & Kyung Hee Sohn.(2025). Development of an identity test for COVID-19 mRNA vaccines using SARS-CoV-2 NAT standard..Biosafety and health, 7(4), 224-227. https: //doi.org/10.1016/J.BSHEAL.2025.07.007.

[5] C. Hage, I. Sengsouk, X. Green, W. Gallo, J. Xue, M. Chahoud... & A. Karaba.(2025). Variant Updated Novavax COVID-19 Vaccination is a Safe Alternative to mRNA Vaccines in Transplant Recipients.American Journal of Transplantation, 25(8S1), S612-S612. https: //doi.org/10.1016/J.AJT.2025.07.1423.

[6] Kathleen M Andersen, Tara Ahi, Jazmine S Mateus, Tiange Yu, Anan Zhou, Santiago M C Lopez & Laura Puzniak. (2025). 2024-2025 BNT162b2 COVID-19 vaccine effectiveness in non-immunocompromised adults: mid-season estimates from vaccine registries in two states linked to administrative claims..Vaccine, 62, 127534. https: //doi.org/10.1016/J.VACCINE.2025.127534.

[7] COVID-19 update: mNEXSPIKE - a new Moderna mRNA vaccine for COVID-19.(2025).The Medical letter on drugs and therapeutics, 67(1733), 119-120. https: //doi.org/10.58347/TML.2025.1733H.

[8] Yuanyi Pan, Yun Han, Chuan Zhou, Lili Zhao, Jie Zheng, Xianwei Ye... & Christopher G. Chute.(2025).Evaluating the safety of XBB.1.5-containing COVID-19 mRNA vaccines using a self-controlled case series study.Nature Communications, 16(1), 6514-6514. https: //doi.org/10.1038/S41467-025-61613-4.

[9] Kanghyun Choi, Joo Young Lee, Uk Il Kim, So Hyun Park, So Hee Hong, Yoo Jin Bang... & Joo Sung Yang. (2025). Discovery and development of a safe and efficient COVID-19 mRNA vaccine, STP2104, using a novel capping library screening method.Frontiers in Immunology, 16, 1571713-1571713. https: //doi.org/10.3389/FIMMU.2025.1571713.

[10] Adewunmi Akingbola, Abiodun Adegbesan, Kolade Adegoke, Courage Idahor, Petra Mariaria, Favour Peters... & Joel Chuku.(2025). Comparing Moderna's mRNA-1083 and Pfizer's dual-target mRNA vaccines for influenza and COVID-19.npj Vaccines, 10(1), 105-105. https: //doi.org/10.1038/S41541-025-01145-6.

[11] Patricia C Lloyd, Elizabeth R Smith, Joann F Gruber, Michelle Ondari, Hui Lee Wong, Mao Hu... & Azadeh Shoaibi.(2025). Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 Months and Older in the United States..Pharmacoepidemiology and drug safety, 34(5), e70151. https: //doi.org/10.1002/PDS.70151.

[12] M Nathaniel Mead, Stephanie Seneff, Russ Wolfinger, Jessica Rose, Kris Denhaerynck, Steve Kirsch & Peter A McCullough.(2024). Retraction: COVID-19 mRNA Vaccines: Lessons Learned from the Registrational Trials and Global Vaccination Campaign. Cureus, 16(2), r137-r137. https: //doi.org/10.7759/CUREUS.R137.